Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesoblast Ltd.

www.mesoblast.com

Latest From Mesoblast Ltd.

Dainippon Closing In On Cell Therapy Specialist Cynata

Australian venture with Phase II-ready cell therapy in sights of Sumitomo Dainippon as Japanese firm looks to build regenerative medicine interests and pipeline ahead of major expiry.

M & A Business Strategies

Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

Cell Therapies Forge Ahead In Japan with Reimbursement, Approval Decisions

A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.

Japan Approvals

Bristol/Celgene A Record-Setting Merger, If It Happens

The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.

Business Strategies M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Mesoblast Ltd.
  • Senior Management
  • Silviu Itescu, CEO & Mng. Dir.
    Paul Hodgkinson , CFO
    Fred Grossman, MD, CMO
  • Contact Info
  • Mesoblast Ltd.
    Phone: (61) 3 9639 6036
    55 Collins St.
    Level 38
    Melbourne, 3000
    Australia
Advertisement
Advertisement
UsernamePublicRestriction

Register